Matthew Pauls - Strongbridge Biopharma CEO and President and Director
CEO
Mr. Matthew Pauls is Chief Executive Officer, Director of the company. since August 2014 and as a member of our board of directors since September 2015. Prior to joining Strongbridge, Mr. Pauls was Chief Commercial Officer of Insmed, Inc., a publicly traded biopharmaceutical company, from April 2013 to August 2014. Prior to Insmed, Mr. Pauls worked at Shire Pharmaceuticals, a publicly traded specialty biopharmaceutical company, beginning in 2007 until March 2013, most recently as Senior Vice President, Head of Global Commercial Operations. Mr. Pauls also held positions at BristolMyers Squibb, a publicly traded pharmaceutical company, in Brand Management and Payor Marketing, and at Johnson Johnson, a publicly traded medical devices, pharmaceutical and consumer packaged goods manufacturer, in various U.S. and global commercial roles. He is a volunteer board member of the Pennington School in Pennington, New Jersey, and the Boys Girls Clubs of Philadelphia since 2014.
| Age | 46 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 610 254 9200 |
| Web | http://www.strongbridgebio.com |
Strongbridge Biopharma Management Efficiency
The company has return on total asset (ROA) of (27.5) % which means that it has lost $27.5 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (87.06) %, meaning that it created substantial loss on money invested by shareholders. Strongbridge Biopharma's management efficiency ratios could be used to measure how well Strongbridge Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 18.68 M in liabilities with Debt to Equity (D/E) ratio of 0.42, which is about average as compared to similar companies. Strongbridge Biopharma has a current ratio of 2.94, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Strongbridge Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Strongbridge Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Strongbridge Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Strongbridge to invest in growth at high rates of return. When we think about Strongbridge Biopharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 6 records | CEO Age | ||
| Brian Kocher | SunOpta | 55 | |
| Darren Jensen | Lifevantage | 46 | |
| Hendrik Jacobs | SunOpta | 53 | |
| Joseph Ennen | SunOpta | 56 | |
| David Colo | SunOpta | 54 | |
| Steven Fife | Lifevantage | 63 | |
Management Performance
| Return On Equity | -87.06 | |||
| Return On Asset | -27.5 |
Strongbridge Biopharma Leadership Team
Elected by the shareholders, the Strongbridge Biopharma's board of directors comprises two types of representatives: Strongbridge Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Strongbridge. The board's role is to monitor Strongbridge Biopharma's management team and ensure that shareholders' interests are well served. Strongbridge Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Strongbridge Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Pauls, CEO and President and Director | ||
| Brian Davis, CFO | ||
| Richard Kollender, Director | ||
| Davis, CFO | ||
| Robert Lutz, Chief Bus. Officer | ||
| Garheng Kong, Director | ||
| John Johnson, Chairman of the Board | ||
| Marten Steen, Director | ||
| Stephen Long, Chief Legal Officer | ||
| Ruth MD, Chief Medical Officer | ||
| Ruth ThieroffEkerdt, Chief Medical Officer | ||
| Marcy Nanus, Vice President - Corporate Affairs | ||
| Hilde Steineger, Director | ||
| Per MD, Founder and Sr. Clinical Advisor | ||
| Scott Wilhoit, Chief Commercial Officer |
Strongbridge Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Strongbridge Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -87.06 | |||
| Return On Asset | -27.5 | |||
| Profit Margin | (115.67) % | |||
| Operating Margin | (123.23) % | |||
| Current Valuation | 85.82 M | |||
| Shares Outstanding | 67.77 M | |||
| Shares Owned By Insiders | 13.64 % | |||
| Shares Owned By Institutions | 67.14 % | |||
| Number Of Shares Shorted | 570.8 K | |||
| Price To Earning | 5.54 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Strongbridge Biopharma information on this page should be used as a complementary analysis to other Strongbridge Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Strongbridge Stock
If you are still planning to invest in Strongbridge Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Strongbridge Biopharma's history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |